|
US7605238B2
(en)
*
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
WO2001014424A2
(en)
*
|
1999-08-24 |
2001-03-01 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
HUP0300423A3
(en)
|
2000-02-10 |
2008-07-28 |
Abbott Lab |
Antibodies that bind human interleukin-18 and methods of making and using
|
|
EP1355666B1
(en)
|
2000-12-22 |
2012-06-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Use of repulsive guidance molecule (RGM) and its modulators
|
|
MX337162B
(es)
|
2001-01-05 |
2016-02-15 |
Pfizer |
Anticuerpos contra el receptor del factor de crecimiento similar a insulina.
|
|
JP4307845B2
(ja)
|
2001-04-26 |
2009-08-05 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Ｃｒｉｐｔｏをブロックする抗体およびその使用
|
|
WO2002092017A2
(en)
|
2001-05-16 |
2002-11-21 |
Albert Einstein College Of Medicine Of Yeshiva University |
Human antipneumococcal antibodies from non-human animals
|
|
IL149701A0
(en)
*
|
2001-05-23 |
2002-11-10 |
Pfizer Prod Inc |
Use of anti-ctla-4 antibodies
|
|
NZ530765A
(en)
|
2001-06-26 |
2006-11-30 |
Amgen Fremont Inc |
Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
|
|
US7521053B2
(en)
*
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
AU2006228095B2
(en)
*
|
2001-10-11 |
2010-11-04 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
DK1527100T3
(da)
|
2002-03-29 |
2009-09-07 |
Schering Corp |
Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme
|
|
BR0309254A
(pt)
|
2002-04-12 |
2005-03-01 |
Medarex Inc |
Uso de um anticorpo anti-ctla-4
|
|
AU2003260871A1
(en)
*
|
2002-09-30 |
2004-04-19 |
Pfizer Products Inc. |
Hybridomas producing high levels of human sequence antibody
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
US7465446B2
(en)
|
2003-05-30 |
2008-12-16 |
Medarex, Inc. |
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
CA2535859A1
(en)
*
|
2003-08-14 |
2005-03-03 |
Dyax Corp. |
Endotheliase-2 ligands
|
|
AR045563A1
(es)
*
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
|
PE20051053A1
(es)
|
2004-01-09 |
2005-12-12 |
Pfizer |
ANTICUERPOS CONTRA MAdCAM
|
|
EP1732600A2
(en)
*
|
2004-03-26 |
2006-12-20 |
Pfizer Products Incorporated |
Uses of anti-ctla-4 antibodies
|
|
US7494779B2
(en)
|
2004-06-14 |
2009-02-24 |
Li-Te Chin |
Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
|
|
CA2601417C
(en)
|
2004-07-01 |
2018-10-30 |
Novo Nordisk A/S |
Human anti-kir antibodies
|
|
JP2008506681A
(ja)
|
2004-07-16 |
2008-03-06 |
ファイザー・プロダクツ・インク |
抗ｉｇｆ−１ｒ抗体を用いる非血液性の悪性腫瘍の併用療法
|
|
EP2899277A1
(en)
*
|
2004-11-26 |
2015-07-29 |
Pieris AG |
Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
|
|
AU2014240252B2
(en)
*
|
2005-03-08 |
2016-10-06 |
Pfizer Products Inc |
Anti-CTLA-4 Antibody Compositions
|
|
AU2012200203B2
(en)
*
|
2005-03-08 |
2014-07-03 |
Pfizer Products Inc. |
Anti-CTLA-4 Antibody Compositions
|
|
NZ560844A
(en)
*
|
2005-03-08 |
2008-08-29 |
Pharmacia & Upjohn Co Llc |
Anti-MAdCAM antibody compositions
|
|
AU2006227879A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Pfizer Products Inc. |
Therapy of prostate cancer with CTLA4 antibodies and hormonal therapy
|
|
JP2006265155A
(ja)
*
|
2005-03-23 |
2006-10-05 |
Link Genomics Kk |
癌の免疫療法
|
|
DK1866339T3
(da)
|
2005-03-25 |
2013-09-02 |
Gitr Inc |
GTR-bindende molekyler og anvendelser heraf
|
|
TW200724548A
(en)
|
2005-04-25 |
2007-07-01 |
Pfizer |
Antibodies to myostatin
|
|
KR101203328B1
(ko)
|
2005-04-26 |
2012-11-20 |
화이자 인코포레이티드 |
Ｐ-카드헤린 항체
|
|
WO2006117910A1
(ja)
|
2005-04-28 |
2006-11-09 |
Mochida Pharmaceutical Co., Ltd. |
抗血小板膜糖蛋白質ⅵモノクローナル抗体
|
|
JP5224707B2
(ja)
*
|
2005-04-28 |
2013-07-03 |
持田製薬株式会社 |
抗血小板膜糖蛋白質ｖｉモノクローナル抗体
|
|
DK2161336T4
(en)
|
2005-05-09 |
2017-04-24 |
Ono Pharmaceutical Co |
Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
|
|
BRPI0611766A2
(pt)
|
2005-06-08 |
2011-12-20 |
Dana Farber Cancer Inst Inc |
métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada
|
|
KR20080030656A
(ko)
*
|
2005-07-07 |
2008-04-04 |
콜레이 파마시티컬 그룹, 인코포레이티드 |
암 치료를 위한 항-ＣＴＬＡ-4 항체 및 ＣｐＧ-모티프-함유합성 올리고데옥시뉴클레오티드의 조합 요법
|
|
CN100443503C
(zh)
*
|
2005-07-18 |
2008-12-17 |
四川大学华西医院 |
人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素
|
|
EP2500356A3
(en)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP2500352A1
(en)
|
2005-08-19 |
2012-09-19 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
CN101517068B
(zh)
|
2005-09-07 |
2017-02-08 |
安进弗里蒙特公司 |
活化素受体样激酶‑1的人单克隆抗体
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
WO2007039256A2
(de)
|
2005-09-30 |
2007-04-12 |
Abbott Gmbh & Co. Kg |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
|
CA2626859A1
(en)
|
2005-11-08 |
2007-05-18 |
Medarex, Inc. |
Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
|
|
PT1976877E
(pt)
|
2005-11-30 |
2014-04-29 |
Abbvie Inc |
Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
|
|
CN117903302A
(zh)
|
2005-11-30 |
2024-04-19 |
Abbvie 公司 |
抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
|
|
CA2630157C
(en)
|
2005-12-07 |
2018-01-09 |
Medarex, Inc. |
Ctla-4 antibody dosage escalation regimens
|
|
JP5093097B2
(ja)
|
2006-03-03 |
2012-12-05 |
小野薬品工業株式会社 |
細胞表面機能分子の細胞外領域多量体
|
|
JP6092497B2
(ja)
|
2006-03-30 |
2017-03-08 |
ユニバーシティー オブ カリフォルニア |
抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
|
|
US7919079B2
(en)
*
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
|
JP2009533028A
(ja)
|
2006-04-07 |
2009-09-17 |
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
新生物疾患の治療のための抗体組成物および方法
|
|
ES2613957T3
(es)
|
2006-08-04 |
2017-05-29 |
Medimmune Limited |
Anticuerpos contra ERBB2
|
|
ES2902063T3
(es)
|
2006-09-08 |
2022-03-24 |
Abbvie Bahamas Ltd |
Proteínas de unión a interleucina-13
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
|
WO2008112193A1
(en)
|
2007-03-12 |
2008-09-18 |
Dana-Farber Cancer Institute |
Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents
|
|
EP2142214A4
(en)
|
2007-04-02 |
2012-03-21 |
Amgen Fremont Inc |
ANTI-IGE ANTIBODY
|
|
ES2776406T3
(es)
|
2007-07-12 |
2020-07-30 |
Gitr Inc |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
|
JP2010540534A
(ja)
|
2007-09-28 |
2010-12-24 |
イントレキソン コーポレーション |
生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用
|
|
AU2008319053B2
(en)
|
2007-11-01 |
2012-04-26 |
Astellas Pharma Inc. |
Immunosuppressive polypeptides and nucleic acids
|
|
ES2425269T3
(es)
|
2007-12-14 |
2013-10-14 |
Bristol-Myers Squibb Company |
Moléculas de unión al receptor OX40 humano
|
|
CN101909693A
(zh)
|
2008-01-08 |
2010-12-08 |
百时美施贵宝公司 |
用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合
|
|
WO2009100140A1
(en)
*
|
2008-02-04 |
2009-08-13 |
Medarex, Inc. |
Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
CA2722466A1
(en)
|
2008-04-29 |
2009-11-05 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
|
MY159667A
(en)
|
2008-05-09 |
2017-01-13 |
Abbvie Inc |
Antibodies to receptor of advanced glycation end products (rage) and uses thereof
|
|
SG191639A1
(en)
|
2008-06-03 |
2013-07-31 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
EP2297208A4
(en)
|
2008-06-03 |
2012-07-11 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
|
EP2810654A1
(en)
|
2008-07-08 |
2014-12-10 |
AbbVie Inc. |
Prostaglandin E2 binding proteins and uses thereof
|
|
KR20110031369A
(ko)
|
2008-07-08 |
2011-03-25 |
아보트 러보러터리즈 |
프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US8119129B2
(en)
|
2008-08-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
ES2658117T3
(es)
|
2008-08-18 |
2018-03-08 |
Pfizer Inc. |
Anticuerpos anti-CCR2
|
|
KR101012267B1
(ko)
*
|
2008-08-29 |
2011-02-08 |
주식회사 세이프로드 |
파손이 방지되는 차선규제봉 및 차선규제봉 시공방법
|
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
|
US8685898B2
(en)
|
2009-01-15 |
2014-04-01 |
Imdaptive, Inc. |
Adaptive immunity profiling and methods for generation of monoclonal antibodies
|
|
EP2810652A3
(en)
|
2009-03-05 |
2015-03-11 |
AbbVie Inc. |
IL-17 binding proteins
|
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
|
CN102822200A
(zh)
|
2009-07-20 |
2012-12-12 |
百时美施贵宝公司 |
对增殖性疾病进行协同性治疗的抗ctla-4抗体与各种治疗方案的组合
|
|
SG178930A1
(en)
|
2009-08-29 |
2012-04-27 |
Abbott Lab |
Therapeutic dll4 binding proteins
|
|
RU2012112550A
(ru)
|
2009-09-01 |
2013-10-10 |
Эбботт Лэборетриз |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
|
US8435516B2
(en)
|
2009-10-12 |
2013-05-07 |
Pfizer Inc. |
Cancer treatment
|
|
TW201119676A
(en)
|
2009-10-15 |
2011-06-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US8420083B2
(en)
|
2009-10-31 |
2013-04-16 |
Abbvie Inc. |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
|
CA2780069C
(en)
|
2009-12-08 |
2018-07-17 |
Abbott Gmbh & Co. Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
|
RU2605928C2
(ru)
|
2010-03-02 |
2016-12-27 |
Эббви Инк. |
Терапевтические dll4-связывающие белки
|
|
CN104744591B
(zh)
|
2010-04-15 |
2022-09-27 |
Abbvie德国有限责任两合公司 |
β淀粉样蛋白结合蛋白
|
|
US8841417B2
(en)
|
2010-05-14 |
2014-09-23 |
Abbvie Inc. |
IL-1 binding proteins
|
|
EP2571577A1
(en)
|
2010-05-17 |
2013-03-27 |
Bristol-Myers Squibb Company |
Improved immunotherapeutic dosing regimens and combinations thereof
|
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
|
EP2601218A4
(en)
|
2010-08-03 |
2015-02-18 |
Abbvie Inc |
VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
|
|
EP3533803B1
(en)
|
2010-08-14 |
2021-10-27 |
AbbVie Inc. |
Anti-amyloid-beta antibodies
|
|
JP6121903B2
(ja)
|
2010-08-19 |
2017-04-26 |
ゾエティス・ベルジャム・エス・アー |
抗ｎｇｆ抗体およびその使用
|
|
BR112013004581A2
(pt)
|
2010-08-26 |
2017-06-27 |
Abbvie Inc |
imunoglobulinas de domínio variável dual e seus usos
|
|
DK2646552T3
(en)
*
|
2010-12-02 |
2017-10-23 |
Pieris Pharmaceuticals Gmbh |
MUTEINES OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR CTLA-4
|
|
MX348152B
(es)
|
2010-12-14 |
2017-06-02 |
Nat Univ Singapore |
Anticuerpo monoclonal humano con especificidad para el virus del dengue serotipo 1 proteina e y sus usos.
|
|
MY163368A
(en)
|
2010-12-21 |
2017-09-15 |
Abbvie Inc |
Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Ｉｌ－１結合蛋白
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
|
TWI687441B
(zh)
|
2011-06-30 |
2020-03-11 |
中外製藥股份有限公司 |
異源二聚化多胜肽
|
|
SG10201505454SA
(en)
|
2011-07-13 |
2015-09-29 |
Abbvie Inc |
Methods and compositions for treating asthma using anti-il-13 antibodies
|
|
WO2013013029A1
(en)
|
2011-07-19 |
2013-01-24 |
The Board Of Trustees Of The University Of Illinois |
Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes
|
|
EP2750768B1
(en)
|
2011-08-30 |
2018-10-03 |
Astex Pharmaceuticals, Inc. |
Decitabine derivative formulations
|
|
TW201323440A
(zh)
|
2011-10-24 |
2013-06-16 |
Abbvie Inc |
抗骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）之免疫結合物
|
|
JP2014534218A
(ja)
|
2011-10-24 |
2014-12-18 |
アッヴィ・インコーポレイテッド |
Ｔｎｆを標的とする免疫結合剤
|
|
BR112014011115A2
(pt)
|
2011-11-08 |
2017-06-13 |
Pfizer |
métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf
|
|
WO2013090635A2
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
|
US9636398B2
(en)
|
2011-12-14 |
2017-05-02 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
|
JP2015508994A
(ja)
|
2011-12-30 |
2015-03-26 |
アッヴィ・インコーポレイテッド |
Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
|
|
MX391536B
(es)
|
2012-01-27 |
2025-03-21 |
Abbvie Deutschland |
Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
|
|
US20150110779A1
(en)
|
2012-03-15 |
2015-04-23 |
Bristol-Myers Squibb Company |
Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
|
|
WO2013142796A2
(en)
|
2012-03-23 |
2013-09-26 |
Bristol-Myers Squibb Company |
Methods of treatments using ctla4 antibodies
|
|
EP2836514A4
(en)
|
2012-04-13 |
2015-12-30 |
Childrens Medical Center |
TIKI INHIBITORS
|
|
NZ701324A
(en)
|
2012-05-04 |
2016-09-30 |
Pfizer |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
|
US20150118244A1
(en)
|
2012-05-10 |
2015-04-30 |
Bristol-Myers Squibb Company |
Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
|
|
CA2873402C
(en)
|
2012-05-15 |
2023-10-24 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
JP6629069B2
(ja)
|
2012-06-06 |
2020-01-15 |
ゾエティス・エルエルシー |
イヌ化抗ｎｇｆ抗体およびその方法
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
TW201402608A
(zh)
|
2012-07-12 |
2014-01-16 |
Abbvie Inc |
Ｉｌ－１結合蛋白質
|
|
AR092219A1
(es)
*
|
2012-08-23 |
2015-04-08 |
Seattle Genetics Inc |
Conjugados anticuerpo-farmaco (adc) que se unen a proteinas 158p1d7
|
|
RU2636043C2
(ru)
|
2012-11-01 |
2017-11-17 |
Эббви Инк. |
Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
|
|
WO2014100542A1
(en)
|
2012-12-21 |
2014-06-26 |
Abbvie, Inc. |
High-throughput antibody humanization
|
|
MX366967B
(es)
|
2013-03-01 |
2019-07-31 |
Astex Pharmaceuticals Inc |
Combinaciones de farmacos.
|
|
US9194873B2
(en)
|
2013-03-14 |
2015-11-24 |
Abbott Laboratories |
HCV antigen-antibody combination assay and methods and compositions for use therein
|
|
MX2015012922A
(es)
|
2013-03-14 |
2016-04-04 |
Ren Liu |
Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular.
|
|
JP6739329B2
(ja)
|
2013-03-14 |
2020-08-12 |
アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ |
Ｈｃｖコア脂質結合ドメインモノクローナル抗体
|
|
CN105209616A
(zh)
|
2013-03-14 |
2015-12-30 |
雅培制药有限公司 |
用于改进的抗体检测的hcv ns3重组抗原及其突变体
|
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
|
CN105324396A
(zh)
|
2013-03-15 |
2016-02-10 |
艾伯维公司 |
针对IL-1β和/或IL-17的双重特异性结合蛋白
|
|
WO2014197885A2
(en)
|
2013-06-07 |
2014-12-11 |
Duke University |
Inhibitors of complement factor h
|
|
SMT201900684T1
(it)
|
2013-08-08 |
2020-03-13 |
Cytune Pharma |
Composizione farmaceutica combinata
|
|
KR102564207B1
(ko)
|
2013-08-08 |
2023-08-10 |
싸이튠 파마 |
Ｉｌ―１５ 및 ｉｌ―１５ｒ 알파 스시 도메인 기반 모듈로카인
|
|
PL3508502T3
(pl)
|
2013-09-20 |
2023-07-17 |
Bristol-Myers Squibb Company |
Kombinacja przeciwciał anty-lag-3 i przeciwciał anty-pd-1 w leczeniu raka
|
|
MY182168A
(en)
|
2013-11-01 |
2021-01-18 |
Pfizer |
Vectors for expression of prostate-associated antigens
|
|
JP2016540042A
(ja)
|
2013-11-05 |
2016-12-22 |
コグネート バイオサービシズ， インコーポレイテッド |
がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
|
|
US20160264670A1
(en)
|
2013-11-06 |
2016-09-15 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
|
WO2015104406A2
(en)
|
2014-01-13 |
2015-07-16 |
Pieris Ag |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
|
PL3148579T3
(pl)
|
2014-05-28 |
2021-07-19 |
Agenus Inc. |
Przeciwciała anty-gitr i sposoby ich zastosowania
|
|
PL3151921T3
(pl)
|
2014-06-06 |
2020-02-28 |
Bristol-Myers Squibb Company |
Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
DK3186281T3
(da)
|
2014-08-28 |
2019-06-11 |
Halozyme Inc |
Kombinationsterapi med et hyaluronan-nedbrydende enzym og en immun-checkpoint-inhibitor
|
|
CA2944085C
(en)
|
2014-09-16 |
2018-04-10 |
Ease Charm Limited |
Anti-egfr antibody and uses of same
|
|
KR20170072244A
(ko)
|
2014-10-10 |
2017-06-26 |
이데라 파마슈티칼즈, 인코포레이티드 |
관문 억제제를 가지는 tlr9 효능제를 이용한 암 치료
|
|
JP6625627B2
(ja)
|
2014-10-14 |
2019-12-25 |
ハロザイム インコーポレイテッド |
アデノシンデアミナーゼ−２（ａｄａ２）、その変異体の組成物およびそれを使用する方法
|
|
WO2016070769A1
(zh)
*
|
2014-11-04 |
2016-05-12 |
北京韩美药品有限公司 |
同时阻断b7/cd28和il6/il6r/gp130信号通路的重组融合蛋白
|
|
CN105597090B
(zh)
*
|
2014-11-14 |
2022-08-23 |
中国科学院上海营养与健康研究所 |
一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用
|
|
LT3221363T
(lt)
|
2014-11-21 |
2020-08-10 |
Bristol-Myers Squibb Company |
Antikūnai prieš cd73 ir jų panaudojimas
|
|
EP3789399A1
(en)
|
2014-11-21 |
2021-03-10 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
MX2017007097A
(es)
|
2014-12-04 |
2017-09-05 |
Bristol Myers Squibb Co |
Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
|
|
CN104387453A
(zh)
*
|
2014-12-08 |
2015-03-04 |
深圳市同康生物医药有限公司 |
树突状细胞靶向肽及编码基因及应用
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
SG10202006538TA
(en)
|
2014-12-23 |
2020-08-28 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
|
MX393750B
(es)
|
2014-12-31 |
2025-03-24 |
Checkmate Pharmaceuticals Inc |
Inmunoterapia antitumoral combinada.
|
|
WO2016127052A1
(en)
|
2015-02-05 |
2016-08-11 |
Bristol-Myers Squibb Company |
Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
|
|
IL292578A
(en)
*
|
2015-02-13 |
2022-06-01 |
Sorrento Therapeutics Inc |
Antibody therapeutics that bind ctla4
|
|
US20180133327A1
(en)
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
|
WO2016154629A1
(en)
|
2015-03-26 |
2016-09-29 |
Woman & Infants' Hospital Of Rhode Island |
Therapy for malignant disease
|
|
EP3797794A1
(en)
|
2015-04-07 |
2021-03-31 |
Cytlimic Inc. |
Medicine comprising a toll like receptor 3 agonist and a lag-3 protein
|
|
NZ738068A
(en)
|
2015-05-06 |
2019-07-26 |
Snipr Tech Ltd |
Altering microbial populations & modifying microbiota
|
|
CN114907271B
(zh)
|
2015-05-22 |
2024-05-07 |
转化药物开发有限责任公司 |
苯甲酰胺和活性化合物的组合物及其使用方法
|
|
JP6797137B2
(ja)
|
2015-05-29 |
2020-12-09 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｏｘ４０に対する抗体およびその使用
|
|
JP6518917B2
(ja)
|
2015-05-29 |
2019-05-29 |
アッヴィ・インコーポレイテッド |
抗ｃｄ４０抗体およびその使用
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
ES2886657T3
(es)
|
2015-06-29 |
2021-12-20 |
Bristol Myers Squibb Co |
Regímenes de dosificación inmunoterapéutica que comprenden pomalidomida y un anticuerpo anti-CS1 para el tratamiento de cáncer
|
|
EP3313886A1
(en)
|
2015-06-29 |
2018-05-02 |
The Rockefeller University |
Antibodies to cd40 with enhanced agonist activity
|
|
MX2018000016A
(es)
|
2015-07-02 |
2019-01-31 |
Otsuka Pharma Co Ltd |
Composiciones farmaceuticas liofilizadas.
|
|
AU2016291817A1
(en)
|
2015-07-16 |
2018-02-22 |
Biolinerx Ltd. |
Compositions and methods for treating cancer
|
|
JP7032311B2
(ja)
|
2015-07-16 |
2022-03-08 |
バイオエクセル セラピューティクス，インコーポレイテッド |
免疫調節を使用してがんを処置するための新規手法
|
|
US20180222990A1
(en)
|
2015-08-04 |
2018-08-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Treatments and Uses and Methods Thereof
|
|
WO2017025871A1
(en)
|
2015-08-07 |
2017-02-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
|
CA2998132A1
(en)
|
2015-09-11 |
2017-03-16 |
Nascent Biotech, Inc. |
Enhanced delivery of drugs to the brain
|
|
EP3370733B1
(en)
|
2015-11-02 |
2021-07-14 |
Board of Regents, The University of Texas System |
Methods of cd40 activation and immune checkpoint blockade
|
|
US20180320136A1
(en)
|
2015-11-03 |
2018-11-08 |
GlycoMimitics, Inc. |
Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
|
|
CA3004530A1
(en)
|
2015-11-07 |
2017-05-11 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
|
ES2926969T3
(es)
|
2015-11-19 |
2022-10-31 |
Bristol Myers Squibb Co |
Anticuerpos contra el receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos
|
|
SG11201804265XA
(en)
|
2015-12-02 |
2018-06-28 |
Agenus Inc |
Antibodies and methods of use thereof
|
|
SG11201804839WA
(en)
|
2015-12-14 |
2018-07-30 |
Macrogenics Inc |
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
|
|
MA43587A
(fr)
|
2016-01-10 |
2018-11-14 |
Modernatx Inc |
Arnm thérapeutiques codant pour des anticorps anti-ctla-4
|
|
KR20230038311A
(ko)
|
2016-03-04 |
2023-03-17 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd73 항체와의 조합 요법
|
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
|
CA3016474A1
(en)
|
2016-03-15 |
2017-09-21 |
Mersana Therapeutics, Inc. |
Napi2b-targeted antibody-drug conjugates and methods of use thereof
|
|
LT3429618T
(lt)
|
2016-03-16 |
2024-05-10 |
Amal Therapeutics Sa |
Imuninės sistemos patikros taško moduliatoriaus ir komplekso, apimančio į ląsteles prasiskverbiantį peptidą, krovinį ir tlr peptido agonistą, derinys, skirtas naudoti medicinoje
|
|
WO2017173091A1
(en)
|
2016-03-30 |
2017-10-05 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
|
|
US20190046638A1
(en)
|
2016-04-01 |
2019-02-14 |
Checkmate Pharmaceuticals, Inc. |
Fc RECEPTOR-MEDIATED DRUG DELIVERY
|
|
AU2017252527A1
(en)
|
2016-04-18 |
2018-11-08 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human CD40 and uses thereof
|
|
EP3449017B1
(en)
|
2016-04-29 |
2021-12-22 |
Board of Regents, The University of Texas System |
Targeted measure of transcriptional activity related to hormone receptors
|
|
US20190298824A1
(en)
|
2016-05-04 |
2019-10-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Albumin-binding immunomodulatory compositions and methods of use thereof
|
|
CA3024509A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
CA3026054A1
(en)
|
2016-05-30 |
2017-12-07 |
Geovax Inc. |
Compositions and methods for generating an immune response to hepatitis b virus
|
|
US10994033B2
(en)
|
2016-06-01 |
2021-05-04 |
Bristol-Myers Squibb Company |
Imaging methods using 18F-radiolabeled biologics
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
CA3026474A1
(en)
|
2016-06-20 |
2017-12-28 |
Kymab Limited |
Anti-pd-l1 and il-2 cytokines
|
|
CA3029426A1
(en)
|
2016-06-30 |
2018-01-04 |
Oncorus, Inc. |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
|
US20190248893A1
(en)
|
2016-07-14 |
2019-08-15 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
NL2017270B1
(en)
*
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
|
KR20190057345A
(ko)
|
2016-09-21 |
2019-05-28 |
아말 테라퓨틱스 에스에이 |
암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
|
|
MX2019003447A
(es)
|
2016-09-27 |
2019-08-29 |
Univ Texas |
Metodos para mejorar la terapia de bloqueo del punto de control inmune mediante la modulacion del microbioma.
|
|
JP2019535015A
(ja)
|
2016-10-03 |
2019-12-05 |
アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ |
患者サンプルにおけるｇｆａｐ状況を評価する改善された方法
|
|
CN110035773B
(zh)
*
|
2016-10-10 |
2023-06-02 |
中美冠科生物技术（太仓）有限公司 |
新型抗ctla4抗体
|
|
CA3039033A1
(en)
|
2016-10-11 |
2018-04-19 |
Cytlimic Inc. |
Medicine
|
|
CN116672456A
(zh)
|
2016-10-12 |
2023-09-01 |
得克萨斯州大学系统董事会 |
用于tusc2免疫治疗的方法和组合物
|
|
KR20240019398A
(ko)
|
2016-10-28 |
2024-02-14 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
|
|
EP3538137A2
(en)
*
|
2016-11-08 |
2019-09-18 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-pd1 and anti-ctla4 antibodies
|
|
CA3041340A1
(en)
|
2016-11-09 |
2018-05-17 |
Agenus Inc. |
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
|
WO2018089423A1
(en)
|
2016-11-09 |
2018-05-17 |
Musc Foundation For Research Development |
Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
|
|
KR102585006B1
(ko)
|
2016-11-17 |
2023-10-05 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물
|
|
JP7080234B2
(ja)
|
2016-11-23 |
2022-06-03 |
トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー |
ベンズアミドおよび活性化合物組成物および使用方法
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
WO2018099539A1
(en)
|
2016-11-29 |
2018-06-07 |
Horst Lindhofer |
Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
|
|
CA3045243A1
(en)
|
2016-12-01 |
2018-06-07 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
JP2020500878A
(ja)
|
2016-12-01 |
2020-01-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
併用療法
|
|
KR20190112263A
(ko)
|
2016-12-12 |
2019-10-04 |
멀티비르 인코포레이티드 |
암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
|
|
TW202508642A
(zh)
|
2016-12-12 |
2025-03-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物與免疫檢查點抑制劑之組合、以及醫藥組成物之用途
|
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
|
EP3585430A4
(en)
*
|
2017-02-21 |
2020-12-09 |
REMD Biotherapeutics, Inc. |
TREATMENT OF CANCER WITH ANTIBODIES THAT BIND TO T-CYTOTOXIC T-LYMPHOCYTES ANTIGEN-4 (CTLA-4)
|
|
WO2018156973A1
(en)
|
2017-02-24 |
2018-08-30 |
Board Of Regents, The University Of Texas System |
Assay for detection of early stage pancreatic cancer
|
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體－藥物結合物之組合療法
|
|
EP3366703B1
(en)
|
2017-02-28 |
2019-04-03 |
Ralf Kleef |
Immune checkpoint therapy with hyperthermia
|
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
|
EP3596469A1
(en)
|
2017-03-12 |
2020-01-22 |
Yeda Research and Development Co., Ltd. |
Methods of diagnosing and prognosing cancer
|
|
CA3052513A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
|
US20210101980A1
(en)
|
2017-03-31 |
2021-04-08 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
AU2018250688B2
(en)
|
2017-04-15 |
2024-07-04 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
|
|
EP3615070A1
(en)
|
2017-04-26 |
2020-03-04 |
Bristol-Myers Squibb Company |
Methods of antibody production that minimize disulfide bond reduction
|
|
AU2018256845B2
(en)
|
2017-04-28 |
2024-03-14 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
|
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
|
CN108948194B
(zh)
*
|
2017-05-19 |
2023-02-17 |
上海药明生物技术有限公司 |
一种新的ctla-4单克隆抗体
|
|
KR20230053001A
(ko)
*
|
2017-05-19 |
2023-04-20 |
우시 바이올로직스 (상하이) 컴퍼니 리미티드 |
세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
|
|
EP3631465A1
(en)
|
2017-05-25 |
2020-04-08 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
|
KR20240149979A
(ko)
|
2017-05-25 |
2024-10-15 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 중쇄 불변 영역을 포함하는 항체
|
|
BR112019018759A2
(pt)
|
2017-05-30 |
2020-05-05 |
Bristol-Myers Squibb Company |
composições compreendendo uma combinação de um anticorpo anti-lag-3, um inibidor da via pd-1, e um agente imunoterápico
|
|
CN118356488A
(zh)
|
2017-05-30 |
2024-07-19 |
百时美施贵宝公司 |
包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
|
|
PT3631454T
(pt)
|
2017-05-30 |
2023-11-23 |
Bristol Myers Squibb Co |
Tratamento de tumores positivos para lag-3
|
|
AU2018275236B2
(en)
|
2017-05-30 |
2024-11-07 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I
|
|
CN110719799A
(zh)
|
2017-06-09 |
2020-01-21 |
俄勒冈州普罗维登斯健康与服务部 |
Cd39和cd103在鉴定用于癌症治疗的人肿瘤反应性t细胞中的应用
|
|
JP7454945B2
(ja)
|
2017-07-03 |
2024-03-25 |
アボット・ラボラトリーズ |
血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
|
|
CR20200076A
(es)
|
2017-07-14 |
2020-06-10 |
Pfizer |
ANTICUERPOS CONTRA MAdCAM
|
|
WO2019014402A1
(en)
|
2017-07-14 |
2019-01-17 |
Innate Tumor Immunity, Inc. |
MODULATORS OF NLRP3
|
|
TWI799432B
(zh)
*
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
|
CA3071755A1
(en)
|
2017-08-03 |
2019-02-07 |
Otsuka Pharmaceutical Co., Ltd. |
Drug compound and purification methods thereof
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
EP3691643A4
(en)
|
2017-09-29 |
2021-06-16 |
Bristol-Myers Squibb Company |
COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
|
|
WO2019070834A1
(en)
|
2017-10-06 |
2019-04-11 |
David Weiner |
MONOCLONAL DNA ANTIBODIES TARGETING CTLA-4 FOR THE TREATMENT AND PREVENTION OF CANCER
|
|
EP3694552A1
(en)
|
2017-10-10 |
2020-08-19 |
Tilos Therapeutics, Inc. |
Anti-lap antibodies and uses thereof
|
|
KR102823603B1
(ko)
|
2017-10-12 |
2025-06-23 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
면역요법을 위한 t 세포 수용체
|
|
WO2019075468A1
(en)
|
2017-10-15 |
2019-04-18 |
Bristol-Myers Squibb Company |
TUMOR TREATMENT METHODS
|
|
EP3704159A1
(en)
|
2017-11-01 |
2020-09-09 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
|
CA3079999A1
(en)
|
2017-11-07 |
2019-05-16 |
The Board Of Regents Of The University Of Texas System |
Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
|
|
EP3717021A1
(en)
|
2017-11-27 |
2020-10-07 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
CN108003238B
(zh)
*
|
2017-11-30 |
2021-02-02 |
常州费洛斯药业科技有限公司 |
一种能特异识别ctla-4的全人源单克隆抗体或抗体片段及其方法和用途
|
|
EP3721233A2
(en)
|
2017-12-09 |
2020-10-14 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
|
|
CA3067055A1
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
|
|
KR102476887B1
(ko)
*
|
2017-12-20 |
2022-12-13 |
하버 바이오메드 (상하이) 컴퍼니 리미티드 |
Ctla-4에 결합하는 항체 및 이의 용도
|
|
WO2019126691A1
(en)
|
2017-12-21 |
2019-06-27 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
KR102813744B1
(ko)
|
2017-12-27 |
2025-05-28 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd40 항체 및 그의 용도
|
|
JP2021508477A
(ja)
|
2017-12-29 |
2021-03-11 |
オンコラス， インコーポレイテッド |
治療用ポリペプチドの腫瘍溶解性ウイルス送達
|
|
CN120192415A
(zh)
|
2018-01-12 |
2025-06-24 |
百时美施贵宝公司 |
抗tim3抗体及其用途
|
|
CA3088542A1
(en)
|
2018-01-22 |
2019-07-25 |
Bristol-Myers Squibb Company |
Compositions and methods of treating cancer
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
EP3752194A4
(en)
|
2018-02-13 |
2022-03-16 |
Checkmate Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY
|
|
CN111819197B
(zh)
|
2018-03-12 |
2025-03-11 |
硕腾服务有限责任公司 |
抗ngf抗体及其方法
|
|
BR112020018585A8
(pt)
|
2018-03-12 |
2022-12-06 |
Inst Nat Sante Rech Med |
Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer
|
|
US12454561B2
(en)
|
2018-03-19 |
2025-10-28 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
|
|
WO2019179388A1
(en)
*
|
2018-03-19 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel anti-ctla-4 antibody polypeptide
|
|
PE20210290A1
(es)
|
2018-03-21 |
2021-02-11 |
Five Prime Therapeutics Inc |
ANTICUERPOS DE UNION A VISTA A pH ACIDO
|
|
KR102761890B1
(ko)
|
2018-03-23 |
2025-02-06 |
브리스톨-마이어스 스큅 컴퍼니 |
Mica 및/또는 micb에 대한 항체 및 그의 용도
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
JP7761995B2
(ja)
|
2018-03-25 |
2025-10-29 |
エスエヌアイピーアール・バイオーム・アーペーエス |
微生物感染症の治療及び予防
|
|
BR112020019251A2
(pt)
|
2018-03-27 |
2021-01-12 |
Board Of Regents, The University Of Texas System |
Compostos com atividade anti-tumor contra células de câncer com mutações de her2 exon 19
|
|
JP2021519771A
(ja)
|
2018-03-30 |
2021-08-12 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
腫瘍を処置する方法
|
|
KR102890791B1
(ko)
|
2018-04-09 |
2025-11-24 |
체크메이트 파마슈티칼스, 인크. |
바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
|
|
IL278090B2
(en)
|
2018-04-18 |
2024-07-01 |
Xencor Inc |
Il-15/il-15rα heterodimeric fc fusion proteins and uses thereof
|
|
CN112867734A
(zh)
|
2018-04-18 |
2021-05-28 |
Xencor股份有限公司 |
包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
|
|
NZ769136A
(en)
|
2018-04-25 |
2024-04-26 |
Innate Tumor Immunity Inc |
Nlrp3 modulators
|
|
EP3810109B1
(en)
|
2018-05-31 |
2024-08-07 |
Peloton Therapeutics, Inc. |
Compounds and compositions for inhibiting cd73
|
|
CN112566643A
(zh)
|
2018-06-12 |
2021-03-26 |
加利福尼亚大学董事会 |
用于治疗癌症的单链双特异性嵌合抗原受体
|
|
MX2021000009A
(es)
|
2018-07-09 |
2021-03-09 |
Five Prime Therapeutics Inc |
Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4).
|
|
NZ771198A
(en)
|
2018-07-11 |
2024-11-29 |
Actym Therapeutics Inc |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
BR112021000303A2
(pt)
|
2018-07-11 |
2021-04-13 |
Five Prime Therapeutics, Inc. |
Anticorpos que se ligam a vista em ph ácido
|
|
EP3823673A4
(en)
|
2018-07-20 |
2022-05-11 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|
|
US12201627B2
(en)
|
2018-08-16 |
2025-01-21 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|
|
WO2020037092A1
(en)
|
2018-08-16 |
2020-02-20 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
|
BR112021002642A2
(pt)
|
2018-08-16 |
2021-05-04 |
Innate Tumor Immunity, Inc. |
compostos de 4-amino-1h-imidazo[4,5-c]quinolina substituídos e métodos aprimorados para a preparação dos mesmos
|
|
EP3617230A1
(en)
|
2018-09-03 |
2020-03-04 |
BioInvent International AB |
Novel antibodies and nucleotide sequences, and uses thereof
|
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
|
US20220073638A1
(en)
|
2018-09-19 |
2022-03-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
|
CN112105633B
(zh)
|
2018-09-21 |
2024-03-12 |
信达生物制药(苏州)有限公司 |
新型白介素2及其用途
|
|
CA3098765A1
(en)
|
2018-09-21 |
2020-03-26 |
Innovent Biologics (Suzhou) Co., Ltd. |
Novel interleukin-2 and use thereof
|
|
EP3860578A1
(en)
|
2018-10-01 |
2021-08-11 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
|
KR102884523B1
(ko)
|
2018-10-03 |
2025-11-10 |
젠코어 인코포레이티드 |
IL-12 이종이량체 Fc-융합 단백질
|
|
TW202035445A
(zh)
|
2018-10-10 |
2020-10-01 |
美商帝洛斯療法股份有限公司 |
抗lap抗體變異體及其用途
|
|
CA3116188A1
(en)
|
2018-10-12 |
2020-04-16 |
Xencor, Inc. |
Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
|
|
JP2022505647A
(ja)
|
2018-10-23 |
2022-01-14 |
ブリストル－マイヤーズ スクイブ カンパニー |
腫瘍の処置方法
|
|
CN113365664A
(zh)
|
2018-10-29 |
2021-09-07 |
梅尔莎纳医疗公司 |
具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
|
|
JP2022512973A
(ja)
|
2018-11-09 |
2022-02-07 |
ピエリアン バイオサイエンシーズ リミテッド ライアビリティ カンパニー |
腫瘍微小環境の組成を測定するための方法及び組成物
|
|
MY205758A
(en)
|
2018-11-16 |
2024-11-12 |
Bristol Myers Squibb Co |
Anti-nkg2a antibodies and uses thereof
|
|
EP3883955A1
(en)
|
2018-11-19 |
2021-09-29 |
Board of Regents, The University of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
|
MX2021006208A
(es)
|
2018-11-28 |
2021-10-01 |
Univ Texas |
Edición por multiplexación del genoma de células inmunitarias para mejorar la funcionalidad y resistencia al entorno supresor.
|
|
ES2971964T3
(es)
|
2018-11-28 |
2024-06-10 |
Inst Nat Sante Rech Med |
Métodos y kit para someter a ensayo el potencial lítico de células efectoras inmunitarias
|
|
CN113348177A
(zh)
|
2018-11-28 |
2021-09-03 |
百时美施贵宝公司 |
包含经修饰的重链恒定区的抗体
|
|
WO2020112493A1
(en)
|
2018-11-29 |
2020-06-04 |
Board Of Regents, The University Of Texas System |
Methods for ex vivo expansion of natural killer cells and use thereof
|
|
EP3891270A1
(en)
|
2018-12-07 |
2021-10-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
|
AU2019396360A1
(en)
|
2018-12-11 |
2021-05-27 |
Theravance Biopharma R&D Ip, Llc |
Naphthyridine and quinoline derivatives useful as ALK5 inhibitors
|
|
EP3897624A1
(en)
|
2018-12-17 |
2021-10-27 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of sulconazole as a furin inhibitor
|
|
CN113490688B
(zh)
|
2018-12-26 |
2025-07-29 |
希望之城公司 |
可活化的被掩蔽的抗ctla4结合蛋白质
|
|
IL284421B2
(en)
|
2018-12-28 |
2025-05-01 |
Transgene |
M2-defective poxvirus
|
|
WO2020150113A1
(en)
|
2019-01-14 |
2020-07-23 |
Innate Tumor Immunity, Inc. |
Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer
|
|
ES2930151T3
(es)
|
2019-01-14 |
2022-12-07 |
Innate Tumor Immunity Inc |
Moduladores heterocíclicos de NLRP3, para su uso en el tratamiento del cáncer
|
|
US12338228B2
(en)
|
2019-01-14 |
2025-06-24 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|
|
KR102865929B1
(ko)
|
2019-01-14 |
2025-09-29 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
Nlrp3 조정제
|
|
SG11202107606VA
(en)
|
2019-01-15 |
2021-08-30 |
Inst Nat Sante Rech Med |
Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
|
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
|
KR20220007850A
(ko)
|
2019-03-13 |
2022-01-19 |
이더알엔에이 이뮤노테라피스 엔브이 |
Mrna 백신
|
|
EP3942024A4
(en)
|
2019-03-18 |
2023-03-22 |
The Regents of the University of California |
ENHANCEMENT OF T LYMPHOCYTE ACTIVATION BY OSCILLATORY FORCES AND MODIFIED ANTIGEN-PRESENTING CELLS
|
|
KR20210146349A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
JP2022527177A
(ja)
|
2019-03-28 |
2022-05-31 |
ブリストル－マイヤーズ スクイブ カンパニー |
腫瘍を処置する方法
|
|
EP3947737A2
(en)
|
2019-04-02 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
EP3947640A4
(en)
|
2019-04-02 |
2022-12-14 |
The Brigham & Women's Hospital, Inc. |
PROCEDURE FOR DETERMINING THE PROGRESSION OF PRIMARY MELANOMA
|
|
US20220160692A1
(en)
|
2019-04-09 |
2022-05-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
|
US20220220480A1
(en)
|
2019-04-17 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
|
JP7556502B2
(ja)
|
2019-05-09 |
2024-09-26 |
フジフィルム セルラー ダイナミクス，インコーポレイテッド |
ヘパトサイトの作製方法
|
|
US10945981B2
(en)
|
2019-05-17 |
2021-03-16 |
Cancer Prevention Pharmaceuticals, Inc. |
Methods for treating familial adenomatous polyposis
|
|
WO2020243563A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures for suitability to immuno-oncology therapy
|
|
CN114127315A
(zh)
|
2019-05-30 |
2022-03-01 |
百时美施贵宝公司 |
鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
|
|
JP2022534981A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
細胞局在化シグネチャーおよび組み合わせ治療
|
|
AU2020286523A1
(en)
|
2019-06-03 |
2022-02-03 |
The University Of Chicago |
Methods and compositions for treating cancer with cancer-targeted adjuvants
|
|
JP7680375B2
(ja)
|
2019-06-03 |
2025-05-20 |
ザ・ユニバーシティ・オブ・シカゴ |
コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物
|
|
US11246906B2
(en)
|
2019-06-11 |
2022-02-15 |
Alkermes Pharma Ireland Limited |
Compositions and methods for subcutaneous administration of cancer immunotherapy
|
|
EP3990008A1
(en)
|
2019-06-27 |
2022-05-04 |
eTheRNA Immunotherapies NV |
Combination therapy
|
|
CN114729383A
(zh)
|
2019-07-02 |
2022-07-08 |
弗莱德哈钦森癌症研究中心 |
重组ad35载体及相关基因疗法改进
|
|
US12435143B2
(en)
|
2019-07-15 |
2025-10-07 |
Intervet Inc. |
Caninized antibodies against canine CTLA-4
|
|
BR112022000604A2
(pt)
|
2019-07-15 |
2022-03-03 |
Intervet Int Bv |
Anticorpos caninizados para ctla-4 humana
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
JPWO2021024742A1
(OSRAM)
*
|
2019-08-06 |
2021-02-11 |
|
|
|
US20220380314A1
(en)
|
2019-09-17 |
2022-12-01 |
Bial - R&D Investments, S.A. |
Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
|
|
CA3150700A1
(en)
|
2019-09-17 |
2021-03-25 |
Renato T. Skerlj |
IMIDAZOLE SUBSTITUTE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
|
|
JP2022548747A
(ja)
|
2019-09-17 |
2022-11-21 |
バイアル－アールアンドディー インベストメンツ ソシエダッド アノニマ |
酸性セラミダーゼ阻害剤としての置換されたｎ－複素環式カルボキサミド及び医薬としてのその使用
|
|
AU2020350689A1
(en)
|
2019-09-19 |
2022-03-31 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
|
EP4031873A1
(en)
|
2019-09-22 |
2022-07-27 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for lag-3 antagonist therapy
|
|
WO2021061789A1
(en)
|
2019-09-23 |
2021-04-01 |
The Regents Of The University Of Michigan |
Compositions and methods for increasing the efficacy of immunotherapies and vaccines
|
|
JP2022549854A
(ja)
|
2019-09-25 |
2022-11-29 |
サーフィス オンコロジー インコーポレイテッド |
抗ｉｌ－２７抗体及びその使用
|
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
|
AU2020358979A1
(en)
|
2019-10-03 |
2022-04-21 |
Xencor, Inc. |
Targeted IL-12 heterodimeric Fc-fusion proteins
|
|
EP4037710A1
(en)
|
2019-10-04 |
2022-08-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
JPWO2021079958A1
(OSRAM)
|
2019-10-25 |
2021-04-29 |
|
|
|
US20220380765A1
(en)
|
2019-11-02 |
2022-12-01 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
KR20220093349A
(ko)
|
2019-11-08 |
2022-07-05 |
브리스톨-마이어스 스큅 컴퍼니 |
흑색종에 대한 lag-3 길항제 요법
|
|
CN114728941A
(zh)
|
2019-11-22 |
2022-07-08 |
施万生物制药研发Ip有限责任公司 |
作为alk5抑制剂的经取代的1,5-萘啶或喹啉
|
|
JPWO2021106978A1
(OSRAM)
|
2019-11-27 |
2021-06-03 |
|
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
IL294085A
(en)
|
2019-12-19 |
2022-08-01 |
Bristol Myers Squibb Co |
Combinations of dgk inhibitors and checkpoint antagonists
|
|
CA3162444C
(en)
|
2019-12-27 |
2024-04-30 |
Hitoshi KATADA |
Anti-ctla-4 antibody and use thereof
|
|
MX2022008412A
(es)
|
2020-01-07 |
2022-08-08 |
Univ Texas |
Variantes de enzima que agotan metiltioadenosina/adenosina mejorada humana para terapia de cancer.
|
|
CN115244052A
(zh)
|
2020-01-10 |
2022-10-25 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
|
KR20220137698A
(ko)
|
2020-02-05 |
2022-10-12 |
라리마 테라퓨틱스, 인코포레이티드 |
Tat 펩티드 결합 단백질 및 이의 용도
|
|
US20230087600A1
(en)
|
2020-02-06 |
2023-03-23 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
|
EP4107173A1
(en)
|
2020-02-17 |
2022-12-28 |
Board of Regents, The University of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
US20230045494A1
(en)
|
2020-02-28 |
2023-02-09 |
Orega Biotech |
Combination therapies based on ctla4 and il-17b inhibitors
|
|
EP4114449A2
(en)
|
2020-03-05 |
2023-01-11 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
|
US20230140384A1
(en)
|
2020-03-09 |
2023-05-04 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
|
WO2021191870A1
(en)
|
2020-03-27 |
2021-09-30 |
Dcprime B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
JP2023519673A
(ja)
|
2020-03-31 |
2023-05-12 |
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー |
置換ピリミジンおよび使用方法
|
|
WO2021207449A1
(en)
|
2020-04-09 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Affinity matured anti-lap antibodies and uses thereof
|
|
EP4136459A1
(en)
|
2020-04-13 |
2023-02-22 |
Abbott Laboratories |
Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample
|
|
WO2021216670A1
(en)
|
2020-04-21 |
2021-10-28 |
University Of Rochester |
Inhibitors of human epididymus protein 4
|
|
WO2021216920A1
(en)
|
2020-04-22 |
2021-10-28 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
EP4149547A4
(en)
|
2020-05-13 |
2024-08-14 |
Adagene AG |
Compositions and methods for treating cancer
|
|
JP2023528223A
(ja)
|
2020-05-13 |
2023-07-04 |
ディスク・メディシン・インコーポレイテッド |
骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体
|
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
EP4153301A2
(en)
|
2020-05-21 |
2023-03-29 |
Board of Regents, The University of Texas System |
T cell receptors with vgll1 specificity and uses thereof
|
|
US20230279116A1
(en)
|
2020-06-03 |
2023-09-07 |
Mv Biotherapeutics Sa |
Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
|
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
|
EP4161653A1
(en)
|
2020-06-03 |
2023-04-12 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
|
JP2023530275A
(ja)
|
2020-06-10 |
2023-07-14 |
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー |
Ａｌｋ５阻害剤として有用なナフチリジン誘導体
|
|
WO2021260675A1
(en)
|
2020-06-24 |
2021-12-30 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
EP4171617A1
(en)
|
2020-06-30 |
2023-05-03 |
Mendus B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
|
KR20230152783A
(ko)
|
2020-07-07 |
2023-11-03 |
칸큐어 엘엘씨 |
Mic 항체 및 결합제 및 이의 사용 방법
|
|
AU2021306613A1
(en)
|
2020-07-07 |
2023-02-02 |
BioNTech SE |
Therapeutic RNA for HPV-positive cancer
|
|
US20230295146A1
(en)
|
2020-07-24 |
2023-09-21 |
The University Of Rochester |
Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
|
|
AU2021311743A1
(en)
|
2020-07-24 |
2023-02-16 |
Amgen Inc. |
Immunogens derived from SARS-CoV-2 spike protein
|
|
WO2022031804A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
|
CN112359052B
(zh)
*
|
2020-08-20 |
2023-01-03 |
山东兴瑞生物科技有限公司 |
抗EpCAM嵌合抗原受体的编码基因、制备方法、具有该基因的质粒、免疫细胞及其应用
|
|
BR112023003427A2
(pt)
|
2020-08-28 |
2023-03-21 |
Bristol Myers Squibb Co |
Terapia com antagonista de lag-3 para carcinoma hepatocelular
|
|
MX2023002326A
(es)
|
2020-08-31 |
2023-03-21 |
Bristol Myers Squibb Co |
Firma de localizacion celular e inmunoterapia.
|
|
KR20230093282A
(ko)
|
2020-10-23 |
2023-06-27 |
브리스톨-마이어스 스큅 컴퍼니 |
폐암에 대한 lag-3 길항제 요법
|
|
KR20230104220A
(ko)
|
2020-11-05 |
2023-07-07 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
Egfr 항원을 표적화하는 조작된 t 세포 수용체 및 사용 방법
|
|
AU2021377699A1
(en)
|
2020-11-13 |
2023-06-15 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
|
US20220162288A1
(en)
|
2020-11-25 |
2022-05-26 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
|
WO2022119841A1
(en)
|
2020-12-01 |
2022-06-09 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
KR20230119179A
(ko)
*
|
2020-12-10 |
2023-08-16 |
우시 바이올로직스 아일랜드 리미티드 |
P-캐드히린에 대한 항체 및 이의 용도
|
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
EP4267617A1
(en)
|
2020-12-24 |
2023-11-01 |
Vib Vzw |
Human ccr8 binders
|
|
CA3206124A1
(en)
|
2020-12-24 |
2022-06-30 |
Vib Vzw |
Non-blocking human ccr8 binders
|
|
EP4267621A1
(en)
|
2020-12-24 |
2023-11-01 |
Vib Vzw |
Murine cross-reactive human ccr8 binders
|
|
WO2022146948A1
(en)
|
2020-12-28 |
2022-07-07 |
Bristol-Myers Squibb Company |
Subcutaneous administration of pd1/pd-l1 antibodies
|
|
AU2021411486A1
(en)
|
2020-12-28 |
2023-06-29 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
EP4271998A1
(en)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
|
WO2022159492A1
(en)
|
2021-01-19 |
2022-07-28 |
William Marsh Rice University |
Bone-specific delivery of polypeptides
|
|
KR20230135075A
(ko)
|
2021-01-22 |
2023-09-22 |
멘두스 비.브이. |
종양 백신접종 방법
|
|
EP4284950A4
(en)
|
2021-01-29 |
2024-12-25 |
Board of Regents, The University of Texas System |
METHODS OF TREATMENT OF CANCER USING KINASE INHIBITORS
|
|
US20220305100A1
(en)
|
2021-03-12 |
2022-09-29 |
Dcprime B.V. |
Methods of vaccination and use of cd47 blockade
|
|
US20240376224A1
(en)
|
2021-04-02 |
2024-11-14 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
EP4070799A1
(en)
|
2021-04-08 |
2022-10-12 |
Nuvamid SA |
Compositions for the improvement of sport performance
|
|
AU2022253474A1
(en)
|
2021-04-08 |
2023-11-16 |
Board Of Regents, The University Of Texas System |
Compounds and methods for theranostic targeting of parp activity
|
|
CA3215049A1
(en)
|
2021-04-10 |
2022-10-13 |
Baiteng ZHAO |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
EP4079310A1
(en)
|
2021-04-20 |
2022-10-26 |
Nuvamid SA |
Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
|
|
JP2024517131A
(ja)
|
2021-04-20 |
2024-04-19 |
アンスティテュ・クリー |
免疫療法における使用のための組成物及び方法
|
|
EP4079311B1
(en)
|
2021-04-20 |
2025-10-01 |
Nuvamid SA |
Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
|
|
JP7742892B2
(ja)
|
2021-04-23 |
2025-09-22 |
ジェンマブ エー／エス |
抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法
|
|
BR112023024169A2
(pt)
|
2021-05-18 |
2024-02-06 |
Abbott Lab |
Métodos para avaliar lesão cerebral em um indivíduo pediátrico
|
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
|
KR20240049794A
(ko)
|
2021-06-07 |
2024-04-17 |
프로비던스 헬스 앤드 서비시즈 - 오레곤 |
Cxcr5, pd-1, 및 icos 발현 종양 반응성 cd4 t 세포 및 그의 용도
|
|
EP4528280A3
(en)
|
2021-06-14 |
2025-07-02 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
WO2022270611A1
(ja)
|
2021-06-25 |
2022-12-29 |
中外製薬株式会社 |
抗ｃｔｌａ－４抗体
|
|
CN119838007A
(zh)
|
2021-06-25 |
2025-04-18 |
中外制药株式会社 |
抗ctla-4抗体的用途
|
|
EP4367269A1
(en)
|
2021-07-05 |
2024-05-15 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
|
CA3225254A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
CA3228262A1
(en)
|
2021-08-04 |
2023-02-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
|
AU2022332285A1
(en)
|
2021-08-23 |
2024-02-15 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
|
CN118715440A
(zh)
|
2021-08-31 |
2024-09-27 |
雅培实验室 |
诊断脑损伤的方法和系统
|
|
WO2023034777A1
(en)
|
2021-08-31 |
2023-03-09 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
|
EP4409294A1
(en)
|
2021-09-30 |
2024-08-07 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
|
AU2022361488A1
(en)
|
2021-10-05 |
2024-05-02 |
Cytovia Therapeutics, Llc |
Natural killer cells and methods of use thereof
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
AR127408A1
(es)
|
2021-10-20 |
2024-01-17 |
Takeda Pharmaceuticals Co |
Composiciones dirigidas a bcma y métodos de uso de las mismas
|
|
US20240409934A1
(en)
|
2021-10-25 |
2024-12-12 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
|
MX2024005053A
(es)
|
2021-10-29 |
2024-05-10 |
Bristol Myers Squibb Co |
Terapia con antagonista del gen de activacion de linfocitos 3 (lag-3) para cancer hematologico.
|
|
EP4433096A1
(en)
|
2021-11-19 |
2024-09-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
|
EP4436998A1
(en)
*
|
2021-11-24 |
2024-10-02 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
|
JP2025503439A
(ja)
|
2021-12-17 |
2025-02-04 |
アボット・ラボラトリーズ |
血液試料におけるｕｃｈ－ｌ１、ｇｆａｐ及び他のバイオマーカーを決定するためのシステム及び方法
|
|
TW202332687A
(zh)
|
2021-12-23 |
2023-08-16 |
比利時商ｅＴｈｅＲＮＡ免疫治療公司 |
免疫刺激性mrna組成物及其用途
|
|
CA3249004A1
(en)
|
2022-01-26 |
2023-08-03 |
Bristol-Myers Squibb Company |
Polytherapy for Hepatocellular Carcinoma
|
|
JP2025507303A
(ja)
|
2022-02-04 |
2025-03-18 |
アボット・ラボラトリーズ |
試料におけるユビキチンカルボキシ末端ヒドロラーゼｌ１及び／又はグリア原線維性酸性タンパク質の存在を検出する又はその量を測定するためのラテラルフロー方法、アッセイ及びデバイス
|
|
MX2024010310A
(es)
|
2022-02-25 |
2024-08-28 |
Bristol Myers Squibb Co |
Terapia de combinacion para carcinoma colorrectal.
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
KR20250004645A
(ko)
|
2022-03-08 |
2025-01-08 |
알렌티스 테라퓨틱스 아게 |
T 세포 가용성을 증가시키기 위한 항-클라우딘-1 항체의 사용
|
|
MX2024011278A
(es)
|
2022-03-15 |
2024-09-25 |
Compugen Ltd |
Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer.
|
|
TW202400232A
(zh)
|
2022-03-16 |
2024-01-01 |
日商第一三共股份有限公司 |
多特異性分子與免疫檢查點抑制劑之組合
|
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
US20250235478A1
(en)
|
2022-04-28 |
2025-07-24 |
Musc Foundation For Research Development |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
AU2023274540A1
(en)
|
2022-05-24 |
2024-12-12 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
|
US20250332252A1
(en)
|
2022-06-02 |
2025-10-30 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
IL317461A
(en)
|
2022-06-08 |
2025-02-01 |
Tidal Therapeutics Inc |
Ionized Cationic Lipids and Lipid Nanoparticles and Methods of Synthesis and Use thereof
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
|
CN119654339A
(zh)
|
2022-07-01 |
2025-03-18 |
特兰斯吉恩股份有限公司 |
包含表面活性蛋白-d和tnfsf成员的融合蛋白
|
|
WO2024023750A1
(en)
|
2022-07-28 |
2024-02-01 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
|
|
WO2024028794A1
(en)
|
2022-08-02 |
2024-02-08 |
Temple Therapeutics BV |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
|
EP4583860A1
(en)
|
2022-09-06 |
2025-07-16 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
|
EP4605422A2
(en)
|
2022-10-20 |
2025-08-27 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
|
EP4623072A2
(en)
|
2022-11-21 |
2025-10-01 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
|
KR20250120305A
(ko)
|
2022-12-14 |
2025-08-08 |
아스텔라스 파마 유럽 비.브이. |
Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
|
|
AU2023409221A1
(en)
|
2022-12-21 |
2025-06-12 |
Bristol-Myers Squibb Company |
Combination therapy for lung cancer
|
|
EP4658687A1
(en)
|
2023-01-31 |
2025-12-10 |
University of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2024204629A1
(ja)
|
2023-03-29 |
2024-10-03 |
第一三共株式会社 |
抗ｃｄ２５抗体及び抗ｃｄ２５抗体－薬物コンジュゲート
|
|
WO2024211475A1
(en)
|
2023-04-04 |
2024-10-10 |
Abbott Laboratories |
Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
|
|
WO2024213767A1
(en)
|
2023-04-14 |
2024-10-17 |
Institut National de la Santé et de la Recherche Médicale |
Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
|
|
WO2024226971A1
(en)
|
2023-04-28 |
2024-10-31 |
Abbott Point Of Care Inc. |
Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
|
|
WO2024261302A1
(en)
|
2023-06-22 |
2024-12-26 |
Institut National de la Santé et de la Recherche Médicale |
Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
|
|
WO2025003193A1
(en)
|
2023-06-26 |
2025-01-02 |
Institut National de la Santé et de la Recherche Médicale |
Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
|
|
EP4484445A1
(en)
|
2023-06-26 |
2025-01-01 |
Universität zu Köln |
Hcmv neutralizing antibodies
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
|
WO2025012417A1
(en)
|
2023-07-13 |
2025-01-16 |
Institut National de la Santé et de la Recherche Médicale |
Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025050009A2
(en)
|
2023-09-01 |
2025-03-06 |
Children's Hospital Medical Center |
Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
|
|
EP4590715A1
(en)
|
2023-09-21 |
2025-07-30 |
Domain Therapeutics |
Anti-ccr8 monoclonal antibodies and their therapeutic use
|
|
WO2025061993A1
(en)
|
2023-09-21 |
2025-03-27 |
Domain Therapeutics |
Anti-ccr8 monoclonal antibodies and their therapeutic use
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
EP4574165A1
(en)
|
2023-12-21 |
2025-06-25 |
Egle Therapeutics |
Immunocytokine for cancer treatment
|
|
WO2025133175A1
(en)
|
2023-12-21 |
2025-06-26 |
Egle Therapeutics |
Immunocytokine for cancer treatment
|
|
WO2025145207A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg-depleting agent
|
|
WO2025174825A2
(en)
|
2024-02-12 |
2025-08-21 |
Aera Therapeutics, Inc. |
Delivery compositions
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
EP4658320A1
(en)
|
2024-02-27 |
2025-12-10 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibody drug conjugates
|
|
WO2025202222A1
(en)
|
2024-03-25 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
|
|
WO2025210175A1
(en)
|
2024-04-04 |
2025-10-09 |
Centre National De La Recherche Scientifique |
Mutant csf-1r extracellular domain fusion molecules and therapeutic uses thereof
|
|
WO2025217094A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
|
|
WO2025217096A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|
|
WO2025248505A1
(en)
|
2024-05-31 |
2025-12-04 |
Wayne State University |
Methods for treating endometrial and ovarian hyperproliferative disorders
|